80 related articles for article (PubMed ID: 16998298)
1. [A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor].
Song HJ; Kim YS; Han CH; Jang JY; Kim JH; Cheon YK; Kim YS; Moon JH; Cho YD; Shim CS; Kwon KH; Kim BS
Korean J Hepatol; 2006 Sep; 12(3):449-54. PubMed ID: 16998298
[TBL] [Abstract][Full Text] [Related]
2. COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.
Meechan J
Br J Oral Maxillofac Surg; 2006 Apr; 44(2):163-5. PubMed ID: 16191457
[No Abstract] [Full Text] [Related]
3. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
Hinz B; Dormann H; Brune K
Arthritis Rheum; 2006 Jan; 54(1):282-91. PubMed ID: 16385545
[TBL] [Abstract][Full Text] [Related]
4. Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.
Walter I; Schulz U; Vogelhuber M; Wiedmann K; Endlicher E; Klebl F; Andreesen R; Herr W; Ghibelli L; Hackl C; Wiest R; Reichle A
Med Oncol; 2017 Nov; 34(12):192. PubMed ID: 29098441
[TBL] [Abstract][Full Text] [Related]
5. [A case of advanced hepatocellular carcinoma, in which the tumor almost disappeared by orally administered UFT].
Miyagawa H; Kamioka N; Kohara H; Yuube R; Takahashi T; Nakatoh H; Kawada M; Utsunomiya T; Izumiyama F; Akimori T
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2211-5. PubMed ID: 8239687
[TBL] [Abstract][Full Text] [Related]
6. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
7. Clinical inquiries. Do COX-2 inhibitors worsen renal function?
Wall R; Strickland C; Jamieson B; Lo V
J Fam Pract; 2007 Nov; 56(11):957-8. PubMed ID: 17976347
[No Abstract] [Full Text] [Related]
8. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.
Tachimori A; Yamada N; Amano R; Ohira M; Hirakawa K
Anticancer Res; 2008; 28(2A):629-38. PubMed ID: 18507001
[TBL] [Abstract][Full Text] [Related]
9. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk.
Ashok V; Dash C; Rohan TE; Sprafka JM; Terry PD
Breast; 2011 Feb; 20(1):66-70. PubMed ID: 20724158
[TBL] [Abstract][Full Text] [Related]
10. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer.
Treiber G; Röcken C; Wex T; Malfertheiner P
Z Gastroenterol; 2007 May; 45(5):369-77. PubMed ID: 17503315
[TBL] [Abstract][Full Text] [Related]
11. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
13. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
Depont F; Fourrier A; Merlière Y; Droz C; Amouretti M; Bégaud B; Bénichou J; Moride Y; Velo GP; Sturkenboom M; Blin P; Moore N;
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):891-900. PubMed ID: 17351983
[TBL] [Abstract][Full Text] [Related]
14. Use of cox-2 inhibitors in patients with retinal venous occlusive disease.
Recchia FM; Chen E; Li C; Maguluri S
Retina; 2008 Jan; 28(1):134-7. PubMed ID: 18185149
[TBL] [Abstract][Full Text] [Related]
15. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels.
Nakazawa T; Adachi S; Kitano M; Isobe Y; Kokubu S; Hidaka H; Ono K; Okuwaki Y; Watanabe M; Shibuya A; Saigenji K
Oncology; 2007; 73(1-2):90-7. PubMed ID: 18337620
[TBL] [Abstract][Full Text] [Related]
16. [Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy].
Hirashita T; Nakashima K; Sakai M; Sakai I
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1123-6. PubMed ID: 17637554
[TBL] [Abstract][Full Text] [Related]
17. [A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil].
Shitara K; Munakata M; Kudo T; Muto O; Okada R; Mitobe S; Sakata Y; Kondo M; Ishii E; Yabu K
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2083-6. PubMed ID: 17197759
[TBL] [Abstract][Full Text] [Related]
18. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
Gao YW; Chen YX; Wang ZM; Zhou LD; Li XY; Li LX; Luo QZ; Tian W; Fu CY; Zhou JH
Hepatogastroenterology; 2008; 55(82-83):345-50. PubMed ID: 18613363
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
Qin J; Yuan J; Li L; Liu H; Qin R; Qin W; Chen B; Wang H; Wu K
Biomed Pharmacother; 2009 Mar; 63(3):241-8. PubMed ID: 18617357
[TBL] [Abstract][Full Text] [Related]
20. Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction.
Sørensen R; Abildstrom SZ; Torp-Pedersen C; Gislason GH
J Cardiovasc Nurs; 2008; 23(1):14-9. PubMed ID: 18158501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
